Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2001

View Archived Issues

Millennium granted license to novel target for colorectal cancer

Angiotech to expand phase II study of Paxceed for secondary progressive multiple sclerosis

OSI acquires Gilead's oncology assets

Boehringer Ingelheim and ImmunoGen to develop new TAP product

Phase I trial initiated for nasal administration of interferon beta

Halofuginone enters phase I/II trial for advanced-stage cancer

Lupus kidney disease drug candidate LJP-394 designated an orphan drug in Europe

Squalamine enters phase IIb non-small cell lung cancer trial

Phase II trial of Endostatin for the treatment of neuroendocrine tumors commences

Rec-15/3079 exerts beneficial effects on bladder function without unwanted CNS side effects

Novel peptide antibiotics isolated for the first time from mast cells

Human umbilical cord blood cells in the treatment of stroke

First launch for Lilly's Xigris within days of approval

Novel glutamate AMPA receptor antagonist may have potential in ALS

Morphinan derivatives with high affinity for kappa and mu opioid receptors for Rx of cocaine abuse

Rigel receives milestone from Pfizer for respiratory drug target validation

Regeneron's VEGF Trap enters phase I trial

New class of antifungal agents targeting N-myristoyltransferase designed at Roche

New substituted adenine interferon inducers under study by Japan Energy and Sumitomo

Broad series of 5-HT receptor ligands designed by Pharmacia

Pfizer reveals potential new antiinflammatory/analgesic agents

Japanese patent covers Suntory's new nicotinic acetylcholine receptor agonists

Effective and safe anorectic agents emerge from R&D at Mitsui Chemicals

Novel hydrazide derivatives inhibit apoB-associated lipoprotein secretion

Cell death inhibitors under investigation by Sagami

J-124131: a new antitumor antibiotic identified at Banyu

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.